1. GPCR/G Protein
  2. LPL Receptor

Ozanimod (Synonyms: RPC-1063)

Cat. No.: HY-12288 Purity: 99.66%
Data Sheet SDS Handling Instructions

Ozanimod is a novel, oral, once daily, selective sphingosine 1-phosphate 1 and 5 receptor modulator in development for autoimmune indications including relapsing multiple sclerosis (RMS) and ulcerative colitis (UC).

For research use only. We do not sell to patients.
Ozanimod Chemical Structure

Ozanimod Chemical Structure

CAS No. : 1306760-87-1

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 158 In-stock
5 mg USD 144 In-stock
10 mg USD 228 In-stock
25 mg USD 420 In-stock
50 mg USD 660 In-stock
100 mg USD 1020 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Ozanimod is a novel, oral, once daily, selective sphingosine 1-phosphate 1 and 5 receptor modulator in development for autoimmune indications including relapsing multiple sclerosis (RMS) and ulcerative colitis (UC). Target: sphingosine 1-phosphate 1 and 5 receptor Ozanimod represents a potential franchise in immunology. Ozanimod is the potential next-to-market oral agent for the treatment of relapsing multiple sclerosis. In a Phase 2 trial in patients with RMS, Ozanimod achieved the primary endpoint of reduction in MRI brain lesion activity as well as secondary endpoints measuring effects on other MRI parameters. The overall safety profile of Ozanimod is consistent with the results of prior trials and continues to demonstrate differentiation against other oral agents for treatment of RMS. Ozanimod is also being studied in inflammatory bowel disease (IBD). The TOUCHSTONE Phase 2 trial of Ozanimod in UC met its primary endpoint and all secondary endpoints with statistical significance in patients on the 1.0 mg dose of Ozanimod in the 8-week induction period. The overall safety and tolerability profile of Ozanimod is consistent with the results of the recent Phase 2 trial in RMS, and continues to support the potential for orally administered Ozanimod to significantly improve the treatment paradigm for UC patients. Ozanimod is a novel, oral, once daily, selective sphingosine 1-phosphate 1 and 5 receptor modulator in development for autoimmune indications including relapsing multiple sclerosis (RMS) and ulcerative colitis (UC).

References
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 2.4724 mL 12.3622 mL 24.7243 mL
5 mM 0.4945 mL 2.4724 mL 4.9449 mL
10 mM 0.2472 mL 1.2362 mL 2.4724 mL
Please refer to the solubility information to select the appropriate solvent.
References
Molecular Weight

404.46

Formula

C₂₃H₂₄N₄O₃

CAS No.

1306760-87-1

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 29 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Ozanimod
Cat. No.:
HY-12288
Quantity: